- Home
- News
- Blog
- state news
- Andaman And Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra And Nagar Haveli
- Daman And Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
Dr SJS Flora takes charge of Director NIPER Mohali
Chandigarh: Dr SJS Flora has taken over the post of director of NIPER Mohali following the suspension of the previous director Professor Raghuram Rao Akkinepally.
Medical Dialogues has earlier reported that the director of the National Institute of Pharmaceuticals Education and Research (NIPER), Mohali was suspended by NIPER's Board of Governors. Raghuram Rao was given a show-cause letter issued by the government after he failed to implement the orders given by the NIPER's Board of Governors (BoGs) where it asked him to revoke the suspension letter of the institute's registrar.
Read Also: NIPER, Mohali Director given suspension orders
With the position of director following vacant, the charge has now been handed over to Dr Flora, as per recent media reports.
Dr. S.J.S. Flora, Scientist âGâ (Associate Director) was Head, Division of Regulatory Toxicology at Defense Research and Development Establishment, Gwalior. He got his Ph.D. in 1985 from Industrial Toxicology Research Center, Lucknow, India and was a post doctoral fellow at Utah State University, USA (1984-87).
http://www.imedpub.com/editor-profile/Dr_Swaran_Jeet_Singh_Flora/
Dr. S.J.S. Flora's most highlighted contribution has been the development of new molecule engineered for therapy of chronic arsenic and lead poisoning. Mono-isoamyl dimercaptosuccinic acid (MiADMSA) has been designed, synthesized and extensively studies by his group in not only conventional screening models but also in advanced human embryonic stem cells and derived embryoid body. The potential drug has reached the stage of âInvestigational New Drugâ and may soon be undergoing Phase-I clinical trial in collaboration with Cadila Pharma, Ahmedabad.
He has published over 250 research papers in highly rated peer reviewed journals, including more than 50 Review article/chapters in international books, which have been widely cited (> 5000 citation) in international literature. He has held editorial positions at more than 25 prestigious international journals and Guest reviewer of more than 90 international journals. He has recently edited a book 'Handbook of Arsenic Toxicology' published by Elsevier/ Academic Press, New York, USA.
Dr. Flora was awarded â Best New Technology Awardâ of Defence Research & Development Organization (DRDO) for 2009 for developing a new and the first chelating drug in India which may also be the only therapy for chronic arsenic poisoning. He has delivered numerous lectures at many national and international organisations and won many prestigious awards.
Medical Dialogues has earlier reported that the director of the National Institute of Pharmaceuticals Education and Research (NIPER), Mohali was suspended by NIPER's Board of Governors. Raghuram Rao was given a show-cause letter issued by the government after he failed to implement the orders given by the NIPER's Board of Governors (BoGs) where it asked him to revoke the suspension letter of the institute's registrar.
Read Also: NIPER, Mohali Director given suspension orders
With the position of director following vacant, the charge has now been handed over to Dr Flora, as per recent media reports.
Dr. S.J.S. Flora, Scientist âGâ (Associate Director) was Head, Division of Regulatory Toxicology at Defense Research and Development Establishment, Gwalior. He got his Ph.D. in 1985 from Industrial Toxicology Research Center, Lucknow, India and was a post doctoral fellow at Utah State University, USA (1984-87).
http://www.imedpub.com/editor-profile/Dr_Swaran_Jeet_Singh_Flora/
Dr. S.J.S. Flora's most highlighted contribution has been the development of new molecule engineered for therapy of chronic arsenic and lead poisoning. Mono-isoamyl dimercaptosuccinic acid (MiADMSA) has been designed, synthesized and extensively studies by his group in not only conventional screening models but also in advanced human embryonic stem cells and derived embryoid body. The potential drug has reached the stage of âInvestigational New Drugâ and may soon be undergoing Phase-I clinical trial in collaboration with Cadila Pharma, Ahmedabad.
He has published over 250 research papers in highly rated peer reviewed journals, including more than 50 Review article/chapters in international books, which have been widely cited (> 5000 citation) in international literature. He has held editorial positions at more than 25 prestigious international journals and Guest reviewer of more than 90 international journals. He has recently edited a book 'Handbook of Arsenic Toxicology' published by Elsevier/ Academic Press, New York, USA.
Dr. Flora was awarded â Best New Technology Awardâ of Defence Research & Development Organization (DRDO) for 2009 for developing a new and the first chelating drug in India which may also be the only therapy for chronic arsenic poisoning. He has delivered numerous lectures at many national and international organisations and won many prestigious awards.
Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers. Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here
Next Story
NO DATA FOUND
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd